You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《美股》BioNTech(BNTX.US)次季收入按年倍升勝預期 每股虧損遜預期
BioNTech(BNTX.US)公布2025年第二季財報,受惠與輝瑞(PFE.US)合作的新冠復必泰疫苗收入增加,收入達2.61億歐元,按年升近1.03倍,勝市場預期的1.38億歐元。淨虧損收窄至3.87億歐元,對上財年同期錄虧損8.08億歐元。去年同期業績受與美國國家衛生院(NIH)就疫苗特許費用支付相關和解影響。每股基本及攤薄虧損1.6歐元,遜於市場預期的每股虧損1.41歐元。 公司維持強勁財務狀況,截至6月底,現金、現金等價物及證券投資總額達160億歐元。BioNTech與Bristol Myers Squibb達成全球合作,共同開發及商業化PD-L1xVEGF-A雙特異性抗體候選藥物BNT327,預計第三季將收到15億美元,進一步強化財務狀況。此外,公司收購CureVac以增強mRNA癌症免疫療法研發與製造能力,並獲歐盟委員會批准新型COVID-19疫苗,準備於獲監管機構批准後推出。公司重申2025全年財務指引不變。~
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account